EGFR and neoplasm: In recent years, several prospective and retrospective studies have demonstrated that the frequency of EGFR mutations in patients with SCC was 3.9%‐17.2%, which was higher than expected.15, 16, 17 However, the efficacy of EGFR‐TKIs in EGFR‐mutated lung SCC is still controversial, and the tumor responses in SCC are much lower than ADC after EGFR‐TKIs treatment.